Mizuho Securities analyst Irina Rivkind Koffler reiterated a Hold rating on Dermira (DERM) today and set a price target of $17. The company’s shares closed yesterday at $10.50.
Rivkind Koffler noted:
“We believe valuation rests primarily on lebrikizumab rather than on the Qbrexza hyperhidrosis asset (despite its strong launch). Our investment thesis is therefore unchanged after the quarter. Mgmt. indicated it remains open to strategic partnerships. Our base case valuation for the stock is $17/share.”
According to TipRanks.com, Koffler is a 3-star analyst with an average return of 1.0% and a 39.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Currently, the analyst consensus on Dermira is a Strong Buy with an average price target of $22.14.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.48 and a one-year low of $6.00. Currently, Dermira has an average volume of 2.2M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.
